Overview: Vimentin Immunohistochemistry TestIntroduction: The Vimentin Immunohistochemistry Test detects vimentin to diagnose sarcomas or mesenchymal tumors, causing lumps or pain. Following 2023 WHO guidelines, it uses immunohistochemistry for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected sarcomas.
Other Names: Vimentin IHC Assay, Sarcoma IHC Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: Vimentin testing began in the 1980s with sarcoma research. Immunohistochemistry-based methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects vimentin to diagnose sarcomas or mesenchymal tumors, guides treatment, and evaluates patients with lumps or pain.
Test Parameters: 1. Vimentin Protein
Pretest Condition: No fasting required. Collect tissue via biopsy or surgical resection. Report history of lumps, pain, or soft tissue masses.
Specimen: 0.5-2 cma³ tissue (FFPE). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document lumps, pain, soft tissue masses, or family history of sarcomas. Include current medications, especially chemotherapy.
Consent: Written consent required, detailing the tests purpose, cancer implications, and risks of biopsy or surgery.
Procedural Considerations: Uses immunohistochemistry to detect vimentin in tissue. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for sarcoma diagnosis.
Factors Affecting Result Accuracy: Improper tissue fixation or processing can affect results. Low tissue quality may reduce staining accuracy.
Clinical Significance: Positive vimentin staining suggests sarcomas or mesenchymal tumors, guiding surgery or chemotherapy. Negative staining may require further marker testing.
Specialist Consultation: Consult an oncologist or orthopedic oncologist for result interpretation and treatment planning.
Additional Supporting Tests: Desmin IHC, CD34 IHC, or MRI to confirm sarcoma diagnosis.
Test Limitations: Not specific to one sarcoma type; other mesenchymal tumors may express vimentin. Clinical correlation is needed.
References: WHO Soft Tissue Tumor Guidelines, 2023; American Journal of Surgical Pathology, Miettinen M, 2022.
